In human breast cancer, the HER2 evaluation system and experimental methodology are constantly being updated and revised by a group of expert pathologists and oncologists of the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) [7,8,9] to continuously ameliorate the evaluation of the clinical significance of HER2 assessment. This evidence concerns the gene ERBB2 and breast carcinoma.